Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis

OncoImmunology

Volumn 3, Issue 10, 2014, Pages e958952-1-e958952-3

  Young, Arabella ^a,b   Mittal, Deepak ^a,b   Stannard, Kimberley ^a   Yong, Michelle ^a   Teng, Michele W L ^a,b   Allard, Bertrand ^c   Stagg, John ^c   Smyth, Mark J ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

adenosine; combination therapy; immune checkpoint; metastasis; PD 1; tumor mediated immunosuppression

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ANGIOGENESIS; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; MELANOMA; METASTASIS; NATURAL KILLER CELL; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84938651521     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.958952     Document Type: Article

References (10)

1. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
2. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
3. J.D.Wolchok, H.Kluger, M.K.Callahan, M.A.Postow, N.A.Rizvi, A.M.Lesokhin, N.H.Segal, C.E.Ariyan, R.A.Gordon, K.Reed, Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
4. J.Stagg, U.Divisekera, N.McLaughlin, J.Sharkey, S.Pommey, D.Denoyer, K.M.Dwyer, M.J.Smyth. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Nat Acad Sci USA 2010; 107:1547-52; PMID:20080644; http://dx.doi.org/10.1073/pnas.0908801107
5. S.Loi, S.Pommey, B.Haibe-Kains, P.A.Beavis, P.K.Darcy, M.J.Smyth, J.Stagg. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Nat Acad Sci USA 2013; 110:11091-96; PMID:23776241; http://dx.doi.org/10.1073/pnas.1222251110
6. A.Ohta, E.Gorelik, S.J.Prasad, F.Ronchese, D.Lukashev, M.K.Wong, X.Huang, S.Caldwell, K.Liu, P.Smith, A2A adenosine receptor protects tumors from antitumor T cells. Proc Nat Acad Sci USA 2006; 103:13132-37; PMID:16916931; http://dx.doi.org/10.1073/pnas.0605251103
7. + tumors. Proc Nat Acad Sci USA 2013; 110:14711-16; PMID:23964122; http://dx.doi.org/10.1073/pnas.1308209110
8. 2A receptor. Cancer Res 2014; 74:3652-58; PMID:24986517; http://dx.doi.org/10.1158/0008-5472.CAN-14-0957
9. R.Iannone, L.Miele, P.Maiolino, A.Pinto, S.Morello. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res 2014; 4:172-81; PMID:24660106
10. B.Allard, S.Pommey, M.J.Smyth, J.Stagg. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 2013; 19:5626-35; PMID:23983257; http://dx.doi.org/10.1158/1078-0432.CCR-13-0545